Abstract
The extent to which plasma levels of angiogenic factors in healthy individuals and tumour volume-related variations in colorectal cancer affect the accuracy of circulating angiogenic factors as predictors of colorectal cancer vascularity is unknown. We used enzyme-linked immunosorbant assay to measure plasma vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) levels in colorectal liver metastasis (CLM) patients, and ‘no cancer’ controls. CLM volume was determined from computerized tomography scans, and tumour vessel count and vessel volume from anti-endothelial antibody-stained biopsies. There was a significant (P = 0.03) increase in plasma VEGF level in 29 CLM patients (median 180.3 pg ml−1, iqr 132.5–284.8 pg ml−1) compared with 19 controls (median 125.8 pg ml−1, iqr 58.2–235.9 pg ml−1). There were significant correlations between plasma VEGF and tumour vessel count (r = 0.66, P = 0.03), tumour vessel volume (r = 0.59, P = 0.03), and CLM volume (r = 0.53, P = 0.03). A VEGF level in the upper quartile of the plasma VEGF distribution had a 70% sensitivity and 75% specificity in predicting an upper quartile liver metastasis tumour vessel count. No relation was identified between CLM and plasma bFGF levels. Plasma VEGF level predicted CLM vascularity, despite an overlap with normal levels and tumour volume-related variations. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aherne WA and Dunnill MS (1982). Morphometry, 60–73, Edward Arnold: London
Allen-Mersh TG, Earlam S, Fordy C, Abrams K and Houghton J (1994) Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet 344: 1255–1260
Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C and Selby PJ (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77: 956–964
Basilico C and Moscatelli D (1992) The FGF family of growth factors and oncogenes. Adv Cancer Res 59: 115–165
Chalkley HW (1943) Method for the quantitative morphological analysis of tissue. J Natl Cancer Inst 4: 47–53
Dirix LY, Vermeulen PB, Hubens G, Benoy I, Martin M, DePooter C and Van Oosterom AT (1996) Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 7: 843–848
Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooter C, Martin M and Van Oosterom AT (1997) Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76: 238–243
Dworkin MJ, Burke D, Earlam S, Fordy C and Allen-Mersh TG (1995) Measurement of response to treatment in colorectal liver metastases. Br J Cancer 71: 873–876
Eisma RJ, Spiro JD and Kreutzer DL (1997) Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 174: 513–517
Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4–6
Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC and Harris AL (1995) Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 177: 275–283
Fujimoto K, Ichimori Y, Kakizoe T, Okajima E, Sakamoto H, Sugimura T and Terada M (1991) Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Commun 180: 386–392
Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K and Tanikawa K (1998) Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 93: 249–252
Gasparini G and Harris AL (1995) Clinical importance of the determination of tumor angiogenesis in breast carcinoma; much more than a new prognostic tool. J Clin Oncol 13: 765–782
Kang S-M, Maeda K, Chung Y-S, Onoda N, Ogawa Y, Takatsuka S, Ogawa M, Sawada T, Kakata B, Nishiguchi Y, Ikehara T, Okuno M and Sowa M (1997) Vascular endothelial growth factor expression correlates with hematogenous metastasis and prognosis in colorectal carcinoma. Oncol Rep 4: 381–384
Kondo S, Asano M, Matsuo K, Ohmori I and Suzuki H (1994) Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1221: 211–214
Kumar H, Heer K, Lee PWR, Duthie GS, MacDonald AW, Greenman J, Kerin MJ and Monson JRT (1998) Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 4: 1279–1285
Landriscina M, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B, Crucitti F and Barone C (1998) Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 78: 765–770
Leung DW, Cachianes G, Kuang W-J, Goeddel DV and Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306–1309
Maeda K, Chung YS and Ogawa Y (1996) Prognostic value of vascular endothelial growth factor for gastric carcinoma. Cancer 77: 858–863
Mayers MM, Seshadri R, Raymond W, McCaul K and Horsfall DJ (1998) Tumour microvascularity has no independent prognostic significance for breast cancer. Pathology 30: 105–110
Meyer GE, Yu E, Siegal JA, Petteway JC, Blumenstein BA and Brawer MK (1995) Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 76: 2304–2311
Senger DR, Van De Walter L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM and Dvorak HF (1993) Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12: 303–324
Sluitz G, Tempfer C, Obermair A, Reinthaller A, Gitsch G and Kainz C (1995 a) Serum evaluation of basic fibroblast growth factor in cervical cancer patients. Cancer Lett 94: 227–231
Sluitz G, Tempfer C, Obermair A, Dadak C and Kainz C (1995 b) Serum evaluation of basic fibroblast growth factor in breast cancer patients. Anticancer Res 15: 2675–2678
Takahashi Y, Kitadai Y and Bucana CZ (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res 55: 3964–3968
Terayama N, Terada T and Nakanuma Y (1996) An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue. Histopathology 29: 37–43
Weidner N (1998) Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow [editorial comment]. J Pathol 184: 119–122
Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T and Tominaga T (1996) Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 2: 821–826
Yamamoto S, Koishi I, Kuroda H, Komatsu T, Nanbu K, Sakahara H and Mori T (1997) Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival and analysis of serum VEGF levels. Br J Cancer 76: 1221–1227
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Davies, M., Jonas, S., Kaur, S. et al. Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver metastasis vascularity and volume. Br J Cancer 82, 1004–1008 (2000). https://doi.org/10.1054/bjoc.1999.1033
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1033
Keywords
This article is cited by
-
Levels of VEGF-A mRNA in plasma from patients with colorectal carcinoma as possible surrogate marker of angiogenesis
Journal of Cancer Research and Clinical Oncology (2008)
-
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
British Journal of Cancer (2007)
-
Preoperative Plasma Vascular Endothelial Growth Factor But Not Nitrite Is a Useful Complementary Tumor Marker in Patients With Colorectal Cancer
Diseases of the Colon & Rectum (2006)
-
Hepatic Tumor Growth: Target for Angiogenesis Inhibition?
World Journal of Surgery (2005)
-
Role of Serum Vascular Endothelial Growth Factor in the Prediction of Angiogenesis and Prognosis for Non-small Cell Lung Cancer
Lung (2005)